Bottom line
Is VGHAX a good fund? The bottom line
VGHAX is the Admiral share class of Vanguard Health Care Fund, a managed health care sector mutual fund from Vanguard.
It charges 0.27% — about $27 a year on every $10,000 invested, cheaper than 94% of health care sector funds we track.
It returned +17.4% over one year, +6.7% a year over five years, +7.8% a year over ten (as of Dec 31, 2025, per its prospectus).
With $38.2 billion in net assets and 97 holdings, its largest position is Eli Lilly & Co (8.6%) and the top 10 make up 40.6% of the portfolio.
The closest lower-cost alternative we found is XLV (0.08%, 53% top-holdings overlap).
What stands out
- Low cost: cheaper than 94% of health care sector peers
- 5-year return beat 80% of category peers
- No front-end sales load
- Large and established ($38.2 billion)
Updated Nov 19, 2026
What VGHAX invests in
Vanguard Health Care Fund (the Fund) seeks to provide long-term capital appreciation.
The Fund employs an active management approach. Under normal circumstances, the Fund invests at least 80% of its net assets, plus the amount of any borrowings for investment purposes, in the stocks of companies principally engaged in the development, production, or distribution of products and services related to the health care industry. For purposes of the 80% policy, these companies include, among others, pharmaceutical firms, medical supply companies, and businesses that operate hospitals and other health care facilities, and the Fund may also consider companies engaged in medical, diagnostic, biochemical, and other research and development activities. The Funds advisor strives for a balanced representation of the health care field, searching for the best values in the various subsectors of the industry. The Fund may invest up to 50% of its assets in foreign stocks. The Fund is…
From the fund's prospectus (filed May 28, 2026).
VGHAX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| VGHAX | +17.4% | +6.7% | +7.8% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2025
What VGHAX costs
On a $10,000 investment, VGHAX's 0.27% expense ratio costs about $27 a year. The prospectus estimates $343 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
VGHAX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Eli Lilly & Co | 8.61% |
| 2 | Merck & Co Inc | 5.44% |
| 3 | Johnson & Johnson | 4.83% |
| 4 | AstraZeneca PLC | 4.59% |
| 5 | UnitedHealth Group Inc | 4.05% |
| 6 | Gsk Plc | 3.00% |
| 7 | Edwards Lifesciences Corp | 2.56% |
| 8 | Intuitive Surgical Inc | 2.52% |
| 9 | CVS Health Corp | 2.52% |
| 10 | Cencora Inc | 2.47% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 40.6% of the fund. See all top 25 holdings and asset mix →